ProKidney (NASDAQ:PROK) Shares Up 9.4%

ProKidney Corp. (NASDAQ:PROK - Get Free Report) shot up 9.4% during trading on Tuesday . The stock traded as high as $3.45 and last traded at $3.37. 308,569 shares were traded during trading, a decline of 54% from the average session volume of 664,944 shares. The stock had previously closed at $3.08.

Wall Street Analysts Forecast Growth

Separately, Morgan Stanley began coverage on shares of ProKidney in a research note on Thursday, March 7th. They set an "equal weight" rating and a $3.00 price objective for the company.

ProKidney Stock Performance

The firm has a market cap of $944.88 million, a price-to-earnings ratio of -6.04 and a beta of 0.78. The stock's 50 day simple moving average is $1.91 and its 200-day simple moving average is $1.70.

ProKidney (NASDAQ:PROK - Get Free Report) last issued its quarterly earnings results on Thursday, March 21st. The company reported ($0.09) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.19) by $0.10. On average, analysts expect that ProKidney Corp. will post -0.65 EPS for the current fiscal year.

Insider Buying and Selling at ProKidney

In other ProKidney news, SVP Darin J. Weber sold 84,103 shares of the company's stock in a transaction that occurred on Friday, April 12th. The shares were sold at an average price of $1.73, for a total transaction of $145,498.19. Following the transaction, the senior vice president now owns 189,670 shares in the company, valued at approximately $328,129.10. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In related news, SVP Darin J. Weber sold 16,438 shares of the firm's stock in a transaction on Monday, April 22nd. The shares were sold at an average price of $2.51, for a total transaction of $41,259.38. Following the completion of the transaction, the senior vice president now owns 155,194 shares of the company's stock, valued at $389,536.94. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, SVP Darin J. Weber sold 84,103 shares of the firm's stock in a transaction on Friday, April 12th. The stock was sold at an average price of $1.73, for a total transaction of $145,498.19. Following the transaction, the senior vice president now directly owns 189,670 shares of the company's stock, valued at approximately $328,129.10. The disclosure for this sale can be found here. In the last quarter, insiders have sold 118,879 shares of company stock worth $232,392. 44.99% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in PROK. SG Americas Securities LLC purchased a new position in shares of ProKidney during the third quarter worth $78,000. Jump Financial LLC acquired a new stake in ProKidney during the third quarter valued at $216,000. Federated Hermes Inc. grew its position in ProKidney by 10,984.7% during the fourth quarter. Federated Hermes Inc. now owns 113,286 shares of the company's stock valued at $202,000 after buying an additional 112,264 shares during the period. Finally, Zullo Investment Group Inc. acquired a new stake in ProKidney during the first quarter valued at $32,000. Hedge funds and other institutional investors own 51.59% of the company's stock.

ProKidney Company Profile

ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.